Report: CA stem cell agency needs a restructuring

LOS ANGELES (AP) — A report says California's stem cell agency needs more independent oversight and recommends a restructuring to avoid the appearance of conflict of interest.

The report released Thursday by the Institute of Medicine was impressed with the California Institute for Regenerative Medicine for making the state a major player in stem cell research.

But experts said CIRM could benefit from some changes. They found that too many members of the governing board represent schools that receive funding. Though the report didn't identify any specific cases of conflict, it said the potential is there, and the board should also be at arm's length from the management team and not be involved in day-to-day operations.

California voters in 2004 approved Proposition 71 that formed CIRM. It has distributed about $1.3 billion in grants.

Associated Press
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Join the Conversation!

To comment, the following rules must be followed:

  • No Obscenity, Profanity, Vulgarity, Racism or Violent Descriptions
  • No Negative Community Comparisons
  • No Fighting, Name-calling, or Personal Attacks
  • Multiple Accounts are Not Allowed
  • Stay on Story Topic

Comments may be monitored for inappropriate content, but the station is under no legal obligation to do so.
If you believe a comment violates the above rules, please use the Flagging Tool to alert a Moderator.
Flagging does not guarantee removal.

Multiple violations may result in account suspension.
Decisions to suspend or unsuspend accounts are made by Station Moderators.
Links require admin approval before posting.
Questions may be sent to Please provide detailed information.

powered by Disqus


6450 Papermill Drive Knoxville, TN 37919 Phone - (865) 450-8888; Fax - (865) 450-8869
Copyright © 2014 WVLT-TV Inc. - Designed by Gray Digital Media - Powered by Clickability 182407541 -
Gray Television, Inc.